{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:27:31Z","timestamp":1789788451678,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19877-9","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:03:41Z","timestamp":1760454221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined effect of metformin and ezetimibe on PPAR-\u03b3 and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes"],"prefix":"10.1038","volume":"15","author":[{"given":"Asiyeh","family":"Masaeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Taghi","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Mohammadalipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Ali-Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"suppl","key":"19877_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2023","unstructured":"Han, S. K., Baik, S. K. & Kim, M. Y. Non-alcoholic fatty liver disease: definition and subtypes. Clin. Mol. Hepatol. 29 (suppl), S5\u2013s16 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"Suppl","key":"19877_CR2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29 (Suppl), S32\u2013s42 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"19877_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos, A. F., Silva J\u00fanior, W. S. & Valerio, C. M. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 12 (1), 60 (2020).","journal-title":"Diabetol. Metab. Syndr."},{"issue":"16","key":"19877_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo, P. Nonalcoholic fatty liver disease. N Engl. J. Med. 346 (16), 1221\u20131231 (2002).","journal-title":"N Engl. J. Med."},{"issue":"8","key":"19877_CR5","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","volume":"50","author":"G Marchesini","year":"2001","unstructured":"Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (8), 1844\u20131850 (2001).","journal-title":"Diabetes"},{"key":"19877_CR6","doi-asserted-by":"crossref","unstructured":"Forlani, G. et al. The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. J. Diabetes Res. 2931985 (2016).","DOI":"10.1155\/2016\/2931985"},{"key":"19877_CR7","doi-asserted-by":"crossref","unstructured":"J\u00e4ger, S. et al. Association between the fatty liver index and risk of type 2 diabetes in the EPIC-Potsdam study. PloS One 10 (4), e0124749 (2015).","DOI":"10.1371\/journal.pone.0124749"},{"key":"19877_CR8","doi-asserted-by":"crossref","unstructured":"Bondini, S., Kleiner, D. E., Goodman, Z. D., Gramlich, T. & Younossi, Z. M. Pathologic assessment of non-alcoholic fatty liver disease. Clin. Liver Dis. 11 (1), 17\u201323, vii (2007).","DOI":"10.1016\/j.cld.2007.02.002"},{"key":"19877_CR9","doi-asserted-by":"crossref","unstructured":"Sobolev, V. V. et al. The role of transcription factor PPAR-\u03b3 in the pathogenesis of psoriasis, skin cells, and immune cells. Int. J. Mol. Sci. 23 (17) (2022).","DOI":"10.3390\/ijms23179708"},{"issue":"1","key":"19877_CR10","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","volume":"10","author":"DP Kumar","year":"2020","unstructured":"Kumar, D. P. et al. The PPAR \u03b1\/\u03b3 agonist Saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci. Rep. 10 (1), 9330 (2020).","journal-title":"Sci. Rep."},{"key":"19877_CR11","doi-asserted-by":"publisher","first-page":"1074911","DOI":"10.3389\/fendo.2022.1074911","volume":"13","author":"Y Lin","year":"2022","unstructured":"Lin, Y., Wang, Y., Li, P. F. & PPAR\u03b1 An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. Front. Endocrinol. (Lausanne). 13, 1074911 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"19877_CR12","doi-asserted-by":"publisher","first-page":"154338","DOI":"10.1016\/j.metabol.2020.154338","volume":"114","author":"A Christofides","year":"2021","unstructured":"Christofides, A., Konstantinidou, E., Jani, C. & Boussiotis, V. A. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metab. Clin. Exp. 114, 154338 (2021).","journal-title":"Metab. Clin. Exp."},{"issue":"6","key":"19877_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.5009\/gnl20367","volume":"15","author":"K Pinyopornpanish","year":"2021","unstructured":"Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K. & Chattipakorn, N. Effects of Metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 15 (6), 827\u2013840 (2021).","journal-title":"Gut Liver"},{"key":"19877_CR14","first-page":"101168","volume":"28","author":"T Yasmin","year":"2021","unstructured":"Yasmin, T. et al. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways. Biochem. Biophys. Rep. 28, 101168 (2021).","journal-title":"Biochem. Biophys. Rep."},{"issue":"3","key":"19877_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1074\/jbc.M113.500934","volume":"289","author":"IS Okon","year":"2014","unstructured":"Okon, I. S., Coughlan, K. A. & Zou, M. H. Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells. J. Biol. Chem. 289 (3), 1639\u20131648 (2014).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"19877_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/cbin.10915","volume":"42","author":"R Ke","year":"2018","unstructured":"Ke, R., Xu, Q., Li, C., Luo, L. & Huang, D. Mechanisms of AMPK in the maintenance of ATP balance during energy metabolism. Cell. Biol. Int. 42 (4), 384\u2013392 (2018).","journal-title":"Cell. Biol. Int."},{"issue":"11","key":"19877_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","volume":"23","author":"EA Nutescu","year":"2003","unstructured":"Nutescu, E. A. & Shapiro, N. L. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 23 (11), 1463\u20131474 (2003).","journal-title":"Pharmacotherapy"},{"key":"19877_CR18","doi-asserted-by":"crossref","unstructured":"de Bari, O., Neuschwander-Tetri, B. A., Liu, M., Portincasa, P. & Wang, D. Q. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids 302847 (2012).","DOI":"10.1155\/2012\/302847"},{"issue":"1","key":"19877_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12944-020-1202-5","volume":"19","author":"B Xia","year":"2020","unstructured":"Xia, B. et al. Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters. Lipids Health Dis. 19 (1), 24 (2020).","journal-title":"Lipids Health Dis."},{"issue":"12","key":"19877_CR20","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1007\/s12325-023-02666-z","volume":"40","author":"Q Su","year":"2023","unstructured":"Su, Q. et al. Efficacy and safety of Single-Pill combination of Rosuvastatin and Ezetimibe in Chinese patients with primary hypercholesterolemia inadequately controlled by Statin treatment (ROZEL): A randomized, double-Blind, double dummy, Active-Controlled phase 3 clinical trial. Adv. Ther. 40 (12), 5285\u20135299 (2023).","journal-title":"Adv. Ther."},{"issue":"11","key":"19877_CR21","doi-asserted-by":"publisher","first-page":"166215","DOI":"10.1016\/j.bbadis.2021.166215","volume":"1867","author":"Y Tanaka","year":"2021","unstructured":"Tanaka, Y. & Kamisako, T. Regulation of the expression of cholesterol transporters by lipid-lowering drugs Ezetimibe and pemafibrate in rat liver and intestine. Biochim. Biophys. Acta Mol. Basis Dis. 1867 (11), 166215 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"5","key":"19877_CR22","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1038\/nutd.2016.16","volume":"6","author":"A Firouzjaei","year":"2016","unstructured":"Firouzjaei, A., Li, G. C., Wang, N., Liu, W. X. & Zhu, B. M. Comparative evaluation of the therapeutic effect of Metformin monotherapy with Metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr. Diabetes. 6 (5), e209 (2016).","journal-title":"Nutr. Diabetes"},{"issue":"6","key":"19877_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.4103\/1735-5362.359436","volume":"17","author":"A Asadi","year":"2022","unstructured":"Asadi, A., Goudarzi, F., Ghanadian, M. & Mohammadalipour, A. Evaluation of the osteogenic effect of apigenin on human mesenchymal stem cells by inhibiting inflammation through modulation of NF-\u03baB\/I\u03baB\u03b1. Res. Pharm. Sci. 17 (6), 697\u2013706 (2022).","journal-title":"Res. Pharm. Sci."},{"issue":"Suppl","key":"19877_CR24","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"C Gofton","year":"2023","unstructured":"Gofton, C., Upendran, Y., Zheng, M. H. & George, J. MAFLD: how is it different from NAFLD? Clin. Mol. Hepatol. 29 (Suppl), S17\u2013s31 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"19877_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","volume":"22","author":"M Dharmalingam","year":"2018","unstructured":"Dharmalingam, M. & Yamasandhi, P. G. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 22 (3), 421\u2013428 (2018).","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"5","key":"19877_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","volume":"21","author":"C Caussy","year":"2021","unstructured":"Caussy, C., Aubin, A. & Loomba, R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr. Diab Rep. 21 (5), 15 (2021).","journal-title":"Curr. Diab Rep."},{"issue":"1","key":"19877_CR27","first-page":"16","volume":"4","author":"R Kazemi","year":"2012","unstructured":"Kazemi, R. et al. Metformin in nonalcoholic steatohepatitis: a randomized controlled trial. Middle East. J. Dig. Dis. 4 (1), 16\u201322 (2012).","journal-title":"Middle East. J. Dig. Dis."},{"issue":"4","key":"19877_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/hep.27647","volume":"61","author":"R Loomba","year":"2015","unstructured":"Loomba, R. et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatol 61 (4), 1239\u20131250 (2015).","journal-title":"Hepatol"},{"key":"19877_CR29","doi-asserted-by":"publisher","first-page":"1468476","DOI":"10.3389\/fendo.2024.1468476","volume":"15","author":"B Jiao","year":"2024","unstructured":"Jiao, B., Wang, B., Liu, B., Zhao, J. & Zhang, Y. Potential impact of Ezetimibe on patients with NAFLD\/NASH: a meta-analysis of randomized controlled trials. Front. Endocrinol. (Lausanne). 15, 1468476 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"19877_CR30","doi-asserted-by":"crossref","unstructured":"Herman, R., Kravos, N. A., Jensterle, M., Jane\u017e, A. & Dol\u017ean, V. Metformin and insulin resistance: A review of the underlying mechanisms behind changes in GLUT4-Mediated glucose transport. Int J. Mol. Sci. 23 (3) (2022).","DOI":"10.3390\/ijms23031264"},{"issue":"8","key":"19877_CR31","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1210\/jc.2019-00129","volume":"104","author":"M Cree-Green","year":"2019","unstructured":"Cree-Green, M. et al. Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes. J. Clin. Endocrinol. Metab. 104 (8), 3265\u20133278 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"19877_CR32","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1007\/s10238-023-01051-y","volume":"23","author":"H Zhu","year":"2023","unstructured":"Zhu, H., Jia, Z., Li, Y. R. & Danelisen, I. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. Clin. Exp. Med. 23 (7), 2941\u20132951 (2023).","journal-title":"Clin. Exp. Med."},{"key":"19877_CR33","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan, Y. et al. Association of inflammatory cytokines with Non-Alcoholic fatty liver disease. Front. Immunol. 13, 880298 (2022).","journal-title":"Front. Immunol."},{"key":"19877_CR34","doi-asserted-by":"publisher","first-page":"1201439","DOI":"10.3389\/fimmu.2024.1201439","volume":"15","author":"J Ackermann","year":"2024","unstructured":"Ackermann, J. et al. IL-6 signaling drives self-renewal and alternative activation of adipose tissue macrophages. Front. Immunol. 15, 1201439 (2024).","journal-title":"Front. Immunol."},{"key":"19877_CR35","doi-asserted-by":"crossref","unstructured":"Rafaqat, S., Gluscevic, S., Mercantepe, F., Rafaqat, S. & Klisic, A. Interleukins: pathogenesis in non-alcoholic fatty liver disease. Metabolites 14 (3) (2024).","DOI":"10.3390\/metabo14030153"},{"issue":"2","key":"19877_CR36","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1096\/fj.201800529RR","volume":"33","author":"Z Polianskyte-Prause","year":"2019","unstructured":"Polianskyte-Prause, Z. et al. Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. Faseb J. 33 (2), 2858\u20132869 (2019).","journal-title":"Faseb J."},{"issue":"4","key":"19877_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/metabo14040186","volume":"14","author":"F Perazza","year":"2024","unstructured":"Perazza, F. et al. Metformin and the liver: unlocking the full therapeutic potential. Metabolites 14 (4), 186 (2024).","journal-title":"Metabolites"},{"issue":"12","key":"19877_CR38","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/hq1201.100260","volume":"21","author":"HR Davis","year":"2001","unstructured":"Davis, H. R., Compton, D. S., Hoos, L. & Tetzloff, G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc Biol. 21 (12), 2032\u20132038 (2001).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"4","key":"19877_CR39","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/jcm13040943","volume":"13","author":"N Ferri","year":"2024","unstructured":"Ferri, N., Ruscica, M., Fazio, S. & Corsini, A. Low-Density lipoprotein Cholesterol-Lowering drugs: A narrative review. J. Clin. Med. 13 (4), 943 (2024).","journal-title":"J. Clin. Med."},{"key":"19877_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","volume":"73","author":"L Jia","year":"2011","unstructured":"Jia, L., Betters, J. L. & Yu, L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu. Rev. Physiol. 73, 239\u2013259 (2011).","journal-title":"Annu. Rev. Physiol."},{"issue":"7","key":"19877_CR41","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/bcp.13250","volume":"83","author":"E Dolezelova","year":"2017","unstructured":"Dolezelova, E. et al. Effect of Ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 83 (7), 1380\u20131396 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"19877_CR42","first-page":"3778","volume":"15","author":"Z Zhou","year":"2023","unstructured":"Zhou, Z. et al. Metformin induces M2 polarization via AMPK\/PGC-1\u03b1\/PPAR-\u03b3 pathway to improve peripheral nerve regeneration. Am. J. Transl Res. 15 (5), 3778\u20133792 (2023).","journal-title":"Am. J. Transl Res."},{"key":"19877_CR43","doi-asserted-by":"publisher","first-page":"1022739","DOI":"10.3389\/fgene.2022.1022739","volume":"13","author":"S Goel","year":"2022","unstructured":"Goel, S. et al. Activation of 5\u2019 AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action. Front. Genet. 13, 1022739 (2022). Metformin.","journal-title":"Front. Genet."},{"key":"19877_CR44","doi-asserted-by":"publisher","first-page":"1406493","DOI":"10.3389\/fphar.2024.1406493","volume":"15","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid metabolism to alleviate fat accumulation. Front. Pharmacol. 15, 1406493 (2024). Ezetimibe.","journal-title":"Front. Pharmacol."},{"issue":"8","key":"19877_CR45","doi-asserted-by":"publisher","first-page":"158967","DOI":"10.1016\/j.bbalip.2021.158967","volume":"1866","author":"ML Andrade","year":"2021","unstructured":"Andrade, M. L. et al. PPAR\u03b3-induced upregulation of subcutaneous fat adiponectin secretion, glyceroneogenesis and BCAA oxidation requires mTORC1 activity. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids. 1866 (8), 158967 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"19877_CR46","doi-asserted-by":"crossref","unstructured":"Sun, C., Mao, S., Chen, S., Zhang, W. & Liu, C. PPARs-Orchestrated metabolic homeostasis in the adipose tissue. Int J. Mol. Sci. 22 (16) (2021).","DOI":"10.3390\/ijms22168974"},{"issue":"1","key":"19877_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","volume":"22","author":"Z Omer","year":"2010","unstructured":"Omer, Z. et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 22 (1), 18\u201323 (2010).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"19877_CR48","doi-asserted-by":"publisher","first-page":"106440","DOI":"10.1016\/j.domaniend.2020.106440","volume":"72","author":"F Mohammadpour","year":"2020","unstructured":"Mohammadpour, F., Darmani-Kuhi, H., Mohit, A. & Sohani, M. M. Obesity, insulin resistance, adiponectin, and PPAR-\u03b3 gene expression in broiler chicks fed diets supplemented with fat and green tea (Camellia sinensis) extract. Domest. Anim. Endocrinol. 72, 106440 (2020).","journal-title":"Domest. Anim. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19877-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19877-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19877-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T03:25:24Z","timestamp":1760844324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19877-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19877"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19877-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35884"}}